Treatment

Jeffrey E. Lancet, MD

A Case Study in Secondary AML: Best Practice for Treatment Selection

Published on January 20, 2021 in Treatment

Eunice S. Wang, MD

Is it possible to deliver liposomal daunorubicin and cytarabine on an outpatient basis?

Published on December 7, 2020 in Treatment

Eunice S. Wang, MD

What are the key factors you must take into consideration in determining upfront treatment for patients with high-risk, secondary AML?

Published on November 30, 2020 in Treatment

Naval Daver, MD, Jessica K. Altman, MD, Alexander Perl, MD

Expert Opinions on Common Clinical Challenges in AML

Published on October 14, 2020 in Treatment

Naval Daver, MD, Alexander Perl, MD

Key Updates from ASCO 2020 and EHA 2020: Experts Discuss Data and Implications Important to Clinical Practice

Published on October 7, 2020 in Treatment

Naval Daver, MD, Jessica K. Altman, MD, Alexander Perl, MD

New Advances in AML Discussion

Published on July 10, 2020 in Treatment

Eytan M. Stein, MD

High Rate of IDH1 Mutation Clearance and MRD Negativity in Patients with IDH1 Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Published on May 27, 2020 in Treatment

Alexander Perl, MD

How does quizartinib fit into the treatment paradigm of AML and what are the key aspects that clinicians need to know about this agent?

Published on May 6, 2020 in Treatment

Alexander Perl, MD

How are the results of the phase 3 ADMIRAL trial changing the treatment paradigm for salvage therapy of AML?

Published on May 6, 2020 in Treatment

Naval Daver, MD

Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Published on April 22, 2020 in Treatment